CA2527756C - Agents immunostimulants - Google Patents

Agents immunostimulants Download PDF

Info

Publication number
CA2527756C
CA2527756C CA2527756A CA2527756A CA2527756C CA 2527756 C CA2527756 C CA 2527756C CA 2527756 A CA2527756 A CA 2527756A CA 2527756 A CA2527756 A CA 2527756A CA 2527756 C CA2527756 C CA 2527756C
Authority
CA
Canada
Prior art keywords
schizophyllan
immunostimulating
functional group
polysaccharide
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2527756A
Other languages
English (en)
Other versions
CA2527756A1 (fr
Inventor
Masami Mizu
Seiji Shinkai
Kazuo Sakurai
Kazuya Koumoto
Munenori Numata
Takahiro Matsumoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Mitsui DM Sugar Co Ltd
Original Assignee
Japan Science and Technology Agency
Mitsui Sugar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency, Mitsui Sugar Co Ltd filed Critical Japan Science and Technology Agency
Publication of CA2527756A1 publication Critical patent/CA2527756A1/fr
Application granted granted Critical
Publication of CA2527756C publication Critical patent/CA2527756C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un immunostimulant d'un nouveau type, à savoir un complexe d'un oligonucléotide immunostimulant avec un transporteur très sûr et à effet de transfection élevé. L'invention concerne également la formation d'un complexe comprenant un oligonucléotide immunostimulant et un polysaccharide à liaison .beta.-1,3 (de préférence, un glucane .beta.-1,3 tel que le schizophyllane), qui est ensuite administré comme immunostimulant. Les exemples préférés de l'oligonucléotide immunostimulant comprennent un motif CpG non méthylé. En ce qui concerne le polysaccharide, il est préférable d'utiliser un polysaccharide modifié à l'aide d'un groupe fonctionnel de liaison aux acides nucléiques et/ou cytophile.
CA2527756A 2003-05-15 2004-05-13 Agents immunostimulants Expired - Fee Related CA2527756C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003136876 2003-05-15
JP2003-136876 2003-05-15
PCT/JP2004/006793 WO2004100965A1 (fr) 2003-05-15 2004-05-13 Immunostimulant

Publications (2)

Publication Number Publication Date
CA2527756A1 CA2527756A1 (fr) 2004-11-25
CA2527756C true CA2527756C (fr) 2014-05-06

Family

ID=33447238

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2527756A Expired - Fee Related CA2527756C (fr) 2003-05-15 2004-05-13 Agents immunostimulants

Country Status (8)

Country Link
US (1) US7790189B2 (fr)
EP (1) EP1625850B1 (fr)
JP (1) JP4850512B2 (fr)
KR (1) KR100872472B1 (fr)
CN (1) CN1798563A (fr)
AU (1) AU2004238139B2 (fr)
CA (1) CA2527756C (fr)
WO (1) WO2004100965A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20014256D0 (no) 2001-09-03 2001-09-03 Bjoern Kristiansen Fremstilling av immunstimulerende forbindelse
US7790189B2 (en) * 2003-05-15 2010-09-07 Mitsui Sugar Co., Ltd. Immunostimulating agents
EP1896600A2 (fr) 2005-06-15 2008-03-12 Medimush A/S Polythérapie contre le cancer et kit de composants associé
CA2706617A1 (fr) * 2007-11-26 2009-06-25 Novartis Ag Glucanes avec adjuvant
ES2599908T3 (es) 2007-11-26 2017-02-06 Glaxosmithkline Biologicals Sa Glucanos beta-1,3-enlazados conjugados
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2012008465A1 (fr) * 2010-07-16 2012-01-19 ナパジェン ファーマ，インコーポレテッド Complexe (acide nucléique)-polysaccharide
JP6525455B2 (ja) 2013-09-20 2019-06-05 国立研究開発法人医薬基盤・健康・栄養研究所 免疫賦活活性を有するオリゴヌクレオチド含有複合体及びその用途
JP6383740B2 (ja) * 2014-02-06 2018-08-29 国立研究開発法人科学技術振興機構 ペプチド／β−１，３−グルカン複合体及びそれを含む医薬組成物
JP6501247B2 (ja) * 2014-12-16 2019-04-17 公立大学法人北九州市立大学 免疫賦活用ポリヌクレオチド／シゾフィラン複合体及びそれを含む医薬組成物
CN106148266A (zh) * 2015-04-20 2016-11-23 烟台赛泽生物技术有限公司 一种免疫细胞用培养基及该培养基的添加剂
CN105462922A (zh) * 2015-12-31 2016-04-06 广州赛莱拉干细胞科技股份有限公司 一种增加免疫细胞得率的方法
WO2018174140A1 (fr) 2017-03-23 2018-09-27 ナパジェン ファーマ，インコーポレテッド Inhibiteur d'activité d'adhésion de cellules cancéreuses
CN107126558B (zh) * 2017-04-26 2020-06-23 广州渔跃生物技术有限公司 鸡传染性法氏囊病灭活疫苗及其制备方法
CN108295049B (zh) * 2018-02-12 2020-07-14 中山大学 一种负载抗原的水溶性胺化β-1,3-D-葡聚糖纳米粒子及其制备方法和应用
CN108553479A (zh) * 2018-04-03 2018-09-21 南京大学 阳离子修饰的琼脂糖和核酸药物组合物及制备方法和应用
CA3201815A1 (fr) 2020-11-12 2022-05-19 Daiichi Sankyo Company, Limited Complexe de .beta.-glucane et d'acide nucleique ayant une taille de particule controlee

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JPH04352724A (ja) * 1990-07-27 1992-12-07 Mitsui Toatsu Chem Inc 免疫調節型治療剤
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
ES2245778T3 (es) * 1993-08-11 2006-01-16 Jenner Technologies Vacuna contra el cancer de prostata.
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2267100T5 (es) * 1994-07-15 2011-04-08 The University Of Iowa Research Foundation Oligonucleótidos inmunomoduladores.
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996014873A2 (fr) * 1994-11-16 1996-05-23 Sri International CONJUGUES DE β-GLUCANES LIES PAR COVALENCE UTILISES POUR UNE ADMINISTRATION CIBLEE
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
DE69737231T2 (de) 1996-04-19 2007-10-11 Merial Ltd. Impfung mit nukleinsäuren gegen parvovirus infektionen
JP4111403B2 (ja) * 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
SI20117A (sl) 1996-12-27 2000-06-30 Icn Pharmaceuticals, Inc. Oligoaptameri bogati z G-jem in metode modulacije imunskega odziva
EP0855184A1 (fr) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination
CA2281838A1 (fr) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Utilisation d'acides nucleiques contenant des dinucleotides cpg non methyles dans le traitement des troubles associes aux lipopolysaccharides
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1998055495A2 (fr) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Oligonucleotides immunostimulateurs, compositions correspondantes et leurs procedes d'utilisation
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CA2323929C (fr) * 1998-04-03 2004-03-09 University Of Iowa Research Foundation Procedes et produits servant a stimuler le systeme immunitaire au moyen d'oligonucleotides et de cytokines immunotherapeutiques
WO1999056755A1 (fr) * 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methodes de prevention et de traitement des parasitoses et maladies associees a l'aide d'oligonucleotides cpg
CA2328406A1 (fr) * 1998-05-14 1999-11-18 Hermann Wagner Procedes de regulation de l'hematopoiese au moyen d'oligonucleotides a cpg
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
US5962636A (en) * 1998-08-12 1999-10-05 Amgen Canada Inc. Peptides capable of modulating inflammatory heart disease
AU776288B2 (en) 1998-10-05 2004-09-02 Regents Of The University Of California, The Methods and adjuvants for stimulating mucosal immunity
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
RU2245149C2 (ru) 1999-09-25 2005-01-27 Юниверсити Оф Айова Рисерч Фаундейшн Иммуностимулирующие нуклеиновые кислоты
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
CA2386019C (fr) * 1999-09-27 2011-06-21 Coley Pharmaceutical Group, Inc. Methodes concernant l'interferon induit par acides nucleiques immunostimulateur
DE60038664T2 (de) 1999-11-10 2009-05-28 Japan Science And Technology Agency, Kawaguchi Genträger
WO2001069173A1 (fr) * 2000-03-10 2001-09-20 Spectra Precision Inc. Emetteur et recepteur polyvalents pour la mesure de position
EP1292331A2 (fr) * 2000-06-07 2003-03-19 Biosynexus Incorporated Molecules hybrides arn/adn immunostimulatrices
WO2002072152A1 (fr) * 2001-03-13 2002-09-19 Japan Science And Technology Corporation Supports de gene mettant en oeuvre un polysaccharide et leur procede de production
JP3594915B2 (ja) 2001-08-03 2004-12-02 株式会社ナムコ プログラム、情報記憶媒体及びゲーム装置
EP1450856B1 (fr) * 2001-09-14 2009-11-11 Cytos Biotechnology AG Emballage de cpg dans des particules de type virus : procede de preparation et utilisation correspondante
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US7790189B2 (en) * 2003-05-15 2010-09-07 Mitsui Sugar Co., Ltd. Immunostimulating agents
JP4712333B2 (ja) * 2004-08-31 2011-06-29 独立行政法人科学技術振興機構 ハイブリッド多糖系キャリアーを用いる核酸類の導入方法。
JP2007070307A (ja) * 2005-09-09 2007-03-22 Japan Science & Technology Agency 免疫刺激性複合体
PT2405002E (pt) * 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Composições e métodos para formulações de oligonucleotídeos
JP4878915B2 (ja) * 2006-05-25 2012-02-15 独立行政法人科学技術振興機構 核酸／多糖／カーボンナノチューブ複合体
WO2007139190A1 (fr) * 2006-05-31 2007-12-06 Toray Industries, Inc. Oligonucléotide immunostimulant et son application pharmaceutique thereof
JP2008100919A (ja) * 2006-10-17 2008-05-01 Japan Science & Technology Agency Ｔｈ２細胞関連疾患の予防等に用いられる核酸／多糖複合体
ES2599908T3 (es) * 2007-11-26 2017-02-06 Glaxosmithkline Biologicals Sa Glucanos beta-1,3-enlazados conjugados

Also Published As

Publication number Publication date
US7790189B2 (en) 2010-09-07
CA2527756A1 (fr) 2004-11-25
WO2004100965A1 (fr) 2004-11-25
AU2004238139A1 (en) 2004-11-25
KR20060012005A (ko) 2006-02-06
JP4850512B2 (ja) 2012-01-11
JPWO2004100965A1 (ja) 2006-07-13
EP1625850A1 (fr) 2006-02-15
CN1798563A (zh) 2006-07-05
EP1625850B1 (fr) 2012-02-29
US20080262210A1 (en) 2008-10-23
KR100872472B1 (ko) 2008-12-05
AU2004238139B2 (en) 2009-12-03
EP1625850A4 (fr) 2008-12-24

Similar Documents

Publication Publication Date Title
AU2021202301B2 (en) Complex containing oligonucleotide having immunopotentiating activity and use thereof
CA2527756C (fr) Agents immunostimulants
WO2016152767A1 (fr) COMPLEXE CONTENANT UN OLIGONUCLÉOTIDE CpG ET UN ESPACEUR, AYANT UNE ACTIVITÉ D'IMMUNOPOTENTIALISATION, ET UTILISATION DUDIT COMPLEXE
JP6383740B2 (ja) ペプチド／β−１，３−グルカン複合体及びそれを含む医薬組成物
TW202027786A (zh) 包含抗原肽- 佐劑核苷酸結合物之免疫誘導劑及包含其之醫藥組成物
WO2016098832A1 (fr) Composite polynucléotide/schizophyllane et composition pharmaceutique comprenant celui-ci
WO2021132528A1 (fr) Oligodésoxynucléotide contenant un cpg à chaîne courte avec acide polydésoxyadénylique lié, complexe contenant ledit oligodésoxynucléotide et son utilisation
CN105940012B (zh) 肽/β－1，3－葡聚糖复合体及其制造方法以及含有它的医药组合物
BR122020017002B1 (pt) Usos de oligodesoxinucleotídeos na fabricação de agentes para tratamento ou profilaxia de câncer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220513